Zymeworks (ZYME) Panoramica del titolo
Zymeworks Inc. è una società di biotecnologie che sviluppa bioterapici per il trattamento del cancro, delle infiammazioni e delle malattie autoimmuni. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 6/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
Non sono stati rilevati rischi per ZYME dai nostri controlli di rischio.
ZYME Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Zymeworks Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$27.48 |
| Massimo di 52 settimane | US$31.34 |
| Minimo di 52 settimane | US$15.81 |
| Beta | 1.19 |
| Variazione di 1 mese | 5.41% |
| Variazione a 3 mesi | 18.76% |
| Variazione di 1 anno | 66.65% |
| Variazione a 3 anni | 325.39% |
| Variazione a 5 anni | -7.66% |
| Variazione dall'IPO | 111.38% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Sep 03
ZYME: FDA Ziihera Milestones Will Drive Future Oncology Upside
Analysts have raised their fair value estimate for Zymeworks from $55.28 to $59.89, following a series of price target increases that reflect recent FDA approvals for Ziihera regimens, the Theravance royalty deal, and a broader set of contracted milestone and cash flow opportunities. Analyst Commentary Bullish analysts are broadly positive on Zymeworks, with recent notes highlighting how FDA approvals for Ziihera regimens, the Theravance royalty deal, and partner progress could support the company’s valuation and execution story.Seeking Alpha • Aug 27
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval
Summary Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab’s FDA approval. Zanidatamab’s first-line HER2+ gastroesophageal cancer approval expands the eligible patient population and unlocks a $250M milestone plus 10–20% tiered royalties. ZYME’s near-term upside hinges on commercial execution, label expansions, and integrating durable cash-flow assets like YUPELRI from the pending Theravance acquisition. Valuation reflects expectations of a step change in revenue and cash flow, with the market pricing in both transition potential and execution risk. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 20
ZYME: Theravance Acquisition And Royalty Expansion Will Drive Future Upside Narrative
Zymeworks' analyst fair value estimate has increased from $28.00 to $31.00 as analysts incorporate updated earnings models, account for the fuller impact of the Theravance Biopharma acquisition, and consider a more active sector catalyst calendar that supports the revised price targets across recent research. Analyst Commentary Recent research on Zymeworks points to a more constructive stance on the stock, with several firms updating models to reflect the Theravance Biopharma acquisition and a busier sector catalyst calendar.Recent updates
Aggiornamento narrativa • Sep 03
ZYME: FDA Ziihera Milestones Will Drive Future Oncology Upside
Analysts have raised their fair value estimate for Zymeworks from $55.28 to $59.89, following a series of price target increases that reflect recent FDA approvals for Ziihera regimens, the Theravance royalty deal, and a broader set of contracted milestone and cash flow opportunities. Analyst Commentary Bullish analysts are broadly positive on Zymeworks, with recent notes highlighting how FDA approvals for Ziihera regimens, the Theravance royalty deal, and partner progress could support the company’s valuation and execution story.Seeking Alpha • Aug 27
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval
Summary Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab’s FDA approval. Zanidatamab’s first-line HER2+ gastroesophageal cancer approval expands the eligible patient population and unlocks a $250M milestone plus 10–20% tiered royalties. ZYME’s near-term upside hinges on commercial execution, label expansions, and integrating durable cash-flow assets like YUPELRI from the pending Theravance acquisition. Valuation reflects expectations of a step change in revenue and cash flow, with the market pricing in both transition potential and execution risk. Read the full article on Seeking AlphaAggiornamento narrativa • Jul 20
ZYME: Theravance Acquisition And Royalty Expansion Will Drive Future Upside Narrative
Zymeworks' analyst fair value estimate has increased from $28.00 to $31.00 as analysts incorporate updated earnings models, account for the fuller impact of the Theravance Biopharma acquisition, and consider a more active sector catalyst calendar that supports the revised price targets across recent research. Analyst Commentary Recent research on Zymeworks points to a more constructive stance on the stock, with several firms updating models to reflect the Theravance Biopharma acquisition and a busier sector catalyst calendar.Aggiornamento narrativa • Jul 06
ZYME: Royalty Deal And ADC Progress Will Shape Balanced Outlook
Analysts have raised their average price target on Zymeworks to $37, a $3 increase that they attribute to the Theravance Biopharma acquisition. They view the deal as adding durable royalty cash flows and aligning well with Zymeworks' internal development capabilities.
Aggiornamento narrativa • Jun 22
ZYME: Ovarian Cancer Data And Fast Track Status Will Drive Repricing
Zymeworks’ updated analyst price target has edged down from about $40.08 to $39.23. Analysts point to revised assumptions on long term revenue growth, profit margins, and future P/E as key drivers of the change.Articolo di analisi • Jun 21
Zymeworks (ZYME) Stock Could Be 42.3% Undervalued After Cryo EM Breakthrough
Why Zymeworks’ Cryo‑EM Breakthrough Matters for the Stock Zymeworks (ZYME) just reported a collaboration with Gandeeva Therapeutics that used high resolution cryo electron microscopy to map a small antigen bound to a Zymeworks antibody, sharpening insight into antibody epitope binding. For you as a shareholder or potential investor, the key point is that this work goes beyond a headline partnership announcement and delivers specific structural data, including a 2.6 Å view of nine amino acids...Aggiornamento narrativa • Jun 05
ZYME: Royalty Deal And FDA Milestones Will Support Oncology Upside
Analysts have increased their price target on Zymeworks to $48 from $33, citing the recent $250m Royalty Pharma debt deal as a key support for slightly higher projected revenue growth, modestly stronger profit margins, and a lower future P/E assumption in their updated model. Analyst Commentary Recent research points to improving confidence around Zymeworks, with bullish analysts highlighting the Royalty Pharma debt deal and its impact on financial flexibility and valuation assumptions.Aggiornamento narrativa • May 15
ZYME: Royalty-Focused Model And 2026 Oncology Milestones Will Drive Upside
Narrative Update on Zymeworks Analysts have nudged their outlook on Zymeworks higher, with recent price target moves to $46, $47 and $48 framed around the $250m Royalty Pharma debt deal and a greater focus on royalty income, even as updated assumptions now reflect modestly lower fair value alongside higher discount rates, revenue growth, profit margin and a reduced future P/E multiple. Analyst Commentary Bullish analysts are clustering around a similar message for Zymeworks, with recent research tying higher price targets to the US$250m Royalty Pharma debt deal and a clearer tilt toward royalty income.Aggiornamento narrativa • Apr 29
ZYME: Royalty Model Shift Will Rely On Upcoming HER2 Gastric Trial Data
Narrative Update on Zymeworks Analysts have lifted Zymeworks' implied price target range into the mid to high $40s, citing the $250m Royalty Pharma debt deal and a shift toward a more royalty focused model as key reasons for refining assumptions around profitability and a higher future P/E multiple. Analyst Commentary Recent Street research has been broadly constructive on Zymeworks, with several price target increases clustered in the mid to high $40s.Aggiornamento narrativa • Apr 14
ZYME: Royalty Model Outlook Will Hinge On Upcoming HER2 Gastric Cancer Data
Analysts have raised Zymeworks’ fair value estimate from about $36.46 to $40.08, citing higher price targets in the $46 to $48 range, supportive views on the $250m Royalty Pharma financing, and a shift toward a more royalty-focused business model. Analyst Commentary Recent Street research has focused on Zymeworks’ financing decisions, its pivot toward a royalty-driven model, and the pipeline events that could influence how investors think about execution and valuation.Aggiornamento narrativa • Mar 31
ZYME: Royalty Model Shift And FY26 Catalysts Will Drive Future Upside
Analysts have lifted their Zymeworks price target range into the mid $40s, citing the $250m Royalty Pharma financing and the company's tilt toward a more royalty-focused model, along with upcoming clinical and R&D milestones, as key supports for the higher valuations. Analyst Commentary Bullish analysts are clustering around price targets in the mid US$40s, reflecting a view that the recent US$250m Royalty Pharma financing and the pivot toward royalties could support higher valuations if execution stays on track.Aggiornamento narrativa • Mar 17
ZYME: Royalty Model Shift And Debt Deal Will Drive Future Upside
Narrative Update: Zymeworks Analyst Price Target Shift The analyst price target for Zymeworks has moved from $48.27 to $55.34, with analysts pointing to the recent $250m Royalty Pharma debt deal, a more royalty-focused model, and upcoming clinical and R&D milestones as key factors supporting the higher valuation range cited in recent reports of $46 to $48. Analyst Commentary Bullish analysts are leaning into a more constructive view on Zymeworks, with several price targets now clustered in the mid to high US$40s range.Aggiornamento narrativa • Mar 03
ZYME: Cancer Trial Success And Royalty Potential Will Drive Future Upside
Analysts have raised their price target on Zymeworks from $42.00 to approximately $48.27, citing updated assumptions around revenue growth, profit margins and future P/E expectations. What's in the News Chief Financial and Business Officer Leone Patterson plans to leave Zymeworks in the first quarter of 2026, with her role ending January 9, 2026, and employment concluding January 31, 2026 (company announcement).Aggiornamento narrativa • Feb 17
ZYME: Royalty Model Will Be Supported By Upcoming HER2 Gastric Cancer Data
Analysts have raised their price targets on Zymeworks, with one firm moving to $40 from $37 and another to $25 from $17, citing the company's shift toward a royalty-focused model and expectations around upcoming HERIZON GEA-01 data as key drivers. Analyst Commentary Bullish Takeaways Bullish analysts point to the shift toward a royalty-focused model as a key reason for higher price targets, arguing that recurring royalty streams can support more visible revenue over time.Nuova narrativa • Feb 11
ADC And T Cell Engager Setbacks Will Test Reliance On Milestones Yet Offer Long-Term Upside
Catalysts About Zymeworks Zymeworks is a clinical stage biotechnology company focused on antibody drug conjugates, T cell engagers and partnered biologics for oncology and inflammatory diseases. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Feb 03
ZYME: Royalty Model Will Be Driven By Positive HER2 Gastric Cancer Data
Narrative Update Analysts have nudged their blended price target for Zymeworks higher from about $34.50 to roughly $35.62 as they factor in the company’s shift toward a royalty-focused model around zani, positive HERIZON-GEA data for Ziihera, and updated views on future profitability and P/E assumptions. Analyst Commentary Street research on Zymeworks is clustering around two main themes: the shift toward a royalty-focused model centered on zani, and the impact of recent clinical data for Ziihera and early pipeline assets.Aggiornamento narrativa • Jan 19
ZYME: Royalty Model And Cancer Data Will Drive Future Upside
Analysts have lifted their price targets on Zymeworks into a US$25 to US$42 range, citing the shift toward a royalty-focused model, positive HERIZON-GEA-01 data for Ziihera and Zani, and early but encouraging readouts for ZW191 and ZW251 as key drivers of their updated views. Analyst Commentary Bullish analysts are reacting positively to Zymeworks' shift toward a royalty-focused model and the recent clinical updates for Ziihera, Zani, ZW191, and ZW251.Aggiornamento narrativa • Jan 05
ZYME: Royalty Aggregator Model And Cancer Data Will Drive Future Upside
Analysts have lifted their price targets on Zymeworks into a roughly US$25 to US$42 range, reflecting their views on the company’s shift toward a royalty-focused model, positive HERIZON-GEA-01 data around Ziihera and Zani, and early ZW191 results that feed into higher assumed profit margins and a richer future P/E multiple in updated models. Analyst Commentary Recent Street research on Zymeworks has been broadly constructive, with several firms revisiting their models after the shift toward a royalty-focused setup and fresh clinical data around Ziihera, Zani and ZW191.Aggiornamento narrativa • Dec 18
ZYME: Royalty Model And Cancer Data Will Drive Share Outperformance
The analyst fair value estimate for Zymeworks has been raised from $30.00 to $42.00 per share, as analysts point to stronger than expected HERIZON-GEA-01 efficacy data, an expanding royalty-driven model, and upgraded Street price targets as key drivers of higher growth and margin assumptions. Analyst Commentary Bullish analysts are increasingly framing Zymeworks as a higher quality growth story, citing a transition toward a recurring, royalty-driven revenue model and stronger than expected efficacy data from HERIZON GEA-01.Aggiornamento narrativa • Dec 04
ZYME: Royalty Model Will Benefit From Positive HER2 Gastric Cancer Data
Analysts nudged their fair value estimate for Zymeworks slightly higher, from $34.20 to $34.50. This reflects growing confidence that the company’s shift toward a royalty aggregator model, coupled with strong HERIZON-GEA-01 data for Ziihera and encouraging early ZW191 results, can drive faster revenue growth and improved profitability.Aggiornamento narrativa • Nov 20
ZYME: Recurring Royalty Revenue Will Drive Momentum After Positive Clinical Results
Zymeworks' analyst price target has surged from approximately $24.45 to $34.20 per share. This increase reflects analysts' optimism following the company's positive clinical trial results and strategic shift toward generating recurring royalty revenues.Articolo di analisi • Nov 18
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Climb 30% But Its Business Is Yet to Catch Up
Despite an already strong run, Zymeworks Inc. ( NASDAQ:ZYME ) shares have been powering on, with a gain of 30% in the...Articolo di analisi • Nov 09
Zymeworks Inc. (NASDAQ:ZYME) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a mediocre week for Zymeworks Inc. ( NASDAQ:ZYME ) shareholders, with the stock dropping 14% to US$16.46 in...Aggiornamento narrativa • Nov 05
ZYME: Encouraging Pipeline Data Will Drive Momentum Ahead Of Key Clinical Readouts
Analysts have raised their price target for Zymeworks from $23.68 to $24.45 per share. They cite increased confidence in the company's growth outlook following encouraging clinical data and expanding therapeutic opportunities.Aggiornamento narrativa • Oct 22
Analysts Raise Zymeworks Target on Pipeline Progress While Weighing Risks and Valuation Changes
Analysts have increased their price target for Zymeworks from $21.45 to $23.68 per share. They cite the company's differentiated therapies and upcoming clinical milestones as key drivers for the revised outlook.Aggiornamento narrativa • Oct 08
Oncology And Biologic Therapies Will Unlock Global Opportunities
Analysts have increased their price target for Zymeworks from $20.06 to $21.45, citing improving revenue growth forecasts, stronger projected profit margins, and growing confidence in the momentum of Zanidatamab in biliary tract cancer. Analyst Commentary Recent commentary from street research reflects a mix of optimism and caution surrounding Zymeworks, particularly as the company advances its lead asset, Zanidatamab, in the biliary tract cancer market.Aggiornamento narrativa • Sep 20
Oncology And Biologic Therapies Will Unlock Global Opportunities
Despite raised analyst confidence driven by positive clinical momentum for Zanidatamab and anticipated catalysts, Zymeworks’ consensus analyst price target has been modestly lowered from $21.05 to $20.06. Analyst Commentary Positive momentum for Zanidatamab in biliary tract cancer.Articolo di analisi • Sep 07
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 25% But Growth Is Lacking
The Zymeworks Inc. ( NASDAQ:ZYME ) share price has done very well over the last month, posting an excellent gain of...Articolo di analisi • Aug 10
Zymeworks Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Last week, you might have seen that Zymeworks Inc. ( NASDAQ:ZYME ) released its second-quarter result to the market...Articolo di analisi • Jun 18
There's Reason For Concern Over Zymeworks Inc.'s (NASDAQ:ZYME) Price
There wouldn't be many who think Zymeworks Inc.'s ( NASDAQ:ZYME ) price-to-sales (or "P/S") ratio of 9.1x is worth a...Articolo di analisi • May 14
Analysts Just Shipped A Stunning Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates
Zymeworks Inc. ( NASDAQ:ZYME ) shareholders will have a reason to smile today, with the analysts making substantial...Seeking Alpha • Apr 28
Zymeworks: Poised For Growth With Platform Validation
Summary Zymeworks' FDA approval of Ziihera for HER2-positive biliary tract cancer validates its science, partnerships, and positions it for long-term value creation. Financial stability is evident with $76.3 million in revenue in 2024 and a cash runway extending through late 2027. The robust pipeline includes zanidatamab for additional indications and promising early-stage candidates like ZW171 and ZW209 targeting high-unmet need cancers. Competitive landscape and clinical risks exist, but Zymeworks' innovative biologics and strategic partnerships make it a compelling biotech investment. Read the full article on Seeking AlphaArticolo di analisi • Apr 16
We're Hopeful That Zymeworks (NASDAQ:ZYME) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Rendimenti per gli azionisti
| ZYME | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | 4.0% | -2.1% | -1.1% |
| 1Y | 66.6% | 36.5% | 11.7% |
Ritorno vs Industria: ZYME ha superato il US Biotechs che ha restituito 36.5 % nell'ultimo anno.
Rendimento vs Mercato: ZYME ha superato il mercato US che ha restituito 11.7 % nell'ultimo anno.
Volatilità dei prezzi
| ZYME volatility | |
|---|---|
| ZYME Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Prezzo delle azioni stabile: ZYME non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di ZYME è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2003 | 231 | Ken Galbraith | www.zymeworks.com |
Zymeworks Inc. è una società di biotecnologie che sviluppa bioterapici per il trattamento del cancro, delle infiammazioni e delle malattie autoimmuni. Le piattaforme dell'azienda comprendono la piattaforma di anticorpi multispecifici Azymetric; la piattaforma di coniugati farmacologici, che comprende una serie di citotossine proprietarie che inibiscono la topoisomerasi e la microtubulina, linker stabili e tecnologie di coniugazione; la piattaforma EFECT, che consiste in una serie di modifiche della regione Fc degli anticorpi; e ProTECT, una piattaforma di co-stimolazione immunitaria specifica per il tumore. I suoi principali prodotti candidati includono Ziihera (zanidatamab-hrii), un anticorpo bispecifico che ha come bersaglio i tumori che esprimono l'HER2; zanidatamab per il trattamento di popolazioni neoadiuvanti, del cancro al seno e di altri tumori che esprimono l'HER2; Pasritamig, un engager bispecifico per le cellule T che ha come bersaglio la callicreina umana 2 per il trattamento in monoterapia del cancro alla prostata resistente alla castrazione; ZW191, un coniugato anticorpo-farmaco (ADC) in fase clinica che ha come bersaglio i tumori che esprimono il recettore alfa dei folati, compresi i tumori ovarici, endometriali e del polmone non a piccole cellule; ZW251, una molecola ADC in fase clinica per il trattamento del carcinoma epatocellulare che esprime il glipanico 3; ZW220, un ADC che ha come bersaglio il NSCLC che esprime il NaPi2b e il carcinoma ovarico; ZW209, un nuovo TriTCE che ha come bersaglio le cellule tumorali che esprimono il Delta-like ligand 3 per il trattamento dei tumori solidi; e ZW1528, una molecola bispecifica per il trattamento della broncopneumopatia cronica ostruttiva.
Zymeworks Inc. Riepilogo dei fondamenti
| ZYME statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$1.86b |
| Utili (TTM) | -US$149.99m |
| Ricavi(TTM) | US$37.13m |
52.5x
Rapporto P/S-13.0x
Rapporto P/EZYME è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ZYME Conto economico (TTM) | |
|---|---|
| Ricavi | US$37.13m |
| Costo del fatturato | US$128.71m |
| Profitto lordo | -US$91.58m |
| Altre spese | US$58.41m |
| Utili | -US$149.99m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -2.11 |
| Margine lordo | -246.66% |
| Margine di profitto netto | -404.00% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato ZYME nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/17 00:16 |
| Prezzo dell'azione a fine giornata | 2026/09/17 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Zymeworks Inc. è coperta da 21 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Martin | Bloom Burton & Co. |
| Mayank Mamtani | B. Riley Securities, Inc. |